FDA Brief

Warning letters Drugs

FDA warning letter to

Amneal Pharmaceuticals, LLC

High riskIssued Aug 27, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

What happened

FDA inspected Amneal Pharmaceuticals Private Limited in Gujarat, India, from March 10 to 19, 2025. FDA found inadequate investigations into visible particulate matter in ropivacaine hydrochloride injection bags, including relaxed defect limits and a risk assessment that minimized patient risk. FDA also found bacterial endotoxin test deficiencies, including improper pipetting, rapid gel-clot reading, and non-contemporaneous documentation.

What FDA found

  1. The company did not thoroughly investigate visible particle contamination in ropivacaine injection and continued using polypropylene bags linked to the particles.

    21 CFR 211.192
  2. The company's risk assessment minimized the danger of particles in an epidural injectable and did not adequately consider route of administration or patient population.

    21 CFR 211.192
  3. The company relaxed defect and rejection limits for polypropylene bags, allowing poor-quality bags to be used in sterile injectable production.

    21 CFR 211.192
  4. The company's bacterial endotoxin testing had deficiencies, including incomplete pipette discharge, rapid gel-clot reading, inadequate verification, and non-contemporaneous documentation.

    21 CFR 211.160(b)
  5. The quality unit was not fully exercising its authority and/or responsibilities and lacked sufficient resources.

What FDA wants

FDA asks Amneal to correct the violations promptly and respond in writing within 15 working days with assessments, CAPA plans, and other requested information; if corrective actions cannot be completed in that time, the company must state why and give a schedule. FDA also asks the company to contact CDER's Drug Shortages Staff if an action may disrupt supply.

Who should pay attention

  • hospitals and clinics that use epidural injectables
  • companies buying sterile injectables from contract manufacturers
  • makers and qualifiers of polypropylene bags for parenteral drugs

This is a summary. Read the original letter on fda.gov.

Amneal Pharmaceuticals, LLC's FDA history

Recalls in the last 12 months

Oct 7 Class II Amneal Pharmaceuticals, LLC
Drug
Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08907, NDC 69238-2452-3.
Defective Container; packets were found to be either empty or partially full.
Jun 17 Class III Amneal Pharmaceuticals, LLC
Drug
Primidone Tablets, USP, 50 mg, 100 Tablets per Bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad 382213, INDIA. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater…
Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.
Apr 8 Class II Amneal Pharmaceuticals, LLC
Drug
traMADol Hydrochloride Tablets, USP, 50 mg, 500-count bottles, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382220, India, Distributed by: Amneal Pharmaceuticals LLC, Glasgow, KY 42141, NDC 6021…
Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).
Apr 8 Class I Amneal Pharmaceuticals, LLC
Drug
Magnesium Sulfate in Water for Injection, 4g/100 mL (40mg/mL) IV bag, further packaged in cartons of 12 x 100 mL IV bags, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad, 382110, India, Distributed …
Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Full company page

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  3. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  4. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk